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1. Introduction 
Starting in 1984, the technique of angioplasty was no longer confined to only the treatment 
of peripheral and coronary arteries.  In the original paper investigating the technique of 
angioplasty in cerebral arteries after cerebral vasospasm from aneurysmal subarachnoid 
hemorrhage (aSAH) , Zubkov et al. found an overall decrease in headaches and focal 
neurological deficits after the procedure (Zubkov et al, 1984). Despite advances in both 
medical and endovascular treatment of cerebral vasospasm since then, vasospasm remains a 
prominent source of morbidity and mortality for patients in the Neuro-Intensive Care Unit. 
At an estimated incidence rate of 10-28/100000 people, aSAH is associated with a 20% to 
40% risk of development of symptomatic, cerebral vasospasm. Of these patients 
experiencing symptomatic vasospasm, an estimated 10-15% will die before medical therapy 
while the other 85-90% will have an overall mortality rate of 32-67% (Weant et al, 2010; 
Frontera et al, 2009).  
In a review of the literature investigating endovascular treatment of cerebral vasospasm, an 
absence of standardization is present across these studies. Starting from the basics, the 
literature has not produced a “gold standard” definition of vasospasm. While some groups 
define vasospasm by a clinical ,neurological deterioration (Andaluz et al, 2002), others use a 
variety of diagnostic modalities, such as Transcranial Doppler Velocities (Oskouian et al, 
2002), digital subtraction angiography (Frontera et al, 2009), and narrowing of vessel 
diameter via CT angiography (Coenen et al, 1998), to make the same diagnosis. Therefore, 
assessing the overall efficacy of angioplasty for cerebral vasospasm is difficult when the 
literature provides different indications for the same treatment.  
Once a diagnosis of cerebral vasospasm is confirmed, a lack of standardization continues 
throughout its treatment. While some groups have associated a good neurological grade 
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upon admission to the hospital and an early, clinical response to initial treatment for 
vasospasm with improved outcomes, a treatment regimen for vasospasm is far from 
standardized (Charpentier et al, 1999; Frontera et al, 2010). Although treatment for 
vasospasm differs from hospital to hospital, most studies examining the management of 
vasospasm use a combination of hypervolemia, hemodilution, and hypertension (triple-H) 
therapy as well as the calcium channel blocker nimodipine as their first-line treatments 
(Frontera et al, 2009). Besides applying these two “core” therapies, recent studies have 
tried various combinations of endovascular therapies, such as intra-arterial papaverine 
and verapamil, as well as transluminal balloon angioplasty, first described by Zubkov in 
1984 (Frontera et al, 2009; Zubkov et al, 1984). Despite evidence of improved outcomes 
from papaverine, verapamil, and angioplasty therapies, the absence of a large, 
prospective, multi-center, randomized, controlled trial, evaluating these treatments has 
prevented the creation of a gold standard protocol for treatment of vasospasm (Frontera 
et al, 2009; Zubkov et al, 1984). 
2. Definition of vasospasm 
Zubkov set the stage for investigating the endovascular treatments of vasospasm after 
aneurysmal subarachnoid hemorrhage. Epidemiologically, aneurysms are estimated to be 
present in between 1% and 9% of the population; the incidence of aSAH is around 1 per 
10,000 people and increases with age and female sex (Dupont et al, 2010). While the cause of 
aneurysms and subsequent ruptures are not completely elucidated, risk factors for aSAH 
include smoking, alcohol use, cocaine use, and hypertension (Dupont et al, 2010).  
Cerebral vasospasm after aSAH, macroscopically, is a contraction of smooth muscle in 
cerebral arteries (Al-Tamimi et al, 2010). This contraction, however, is difficult to measure 
and define from direct observation. From the articles reviewed, vasospasm definitions can 
be divided into three categories; groups have defined vasospasm by either clinical 
indications, Transcranial Doppler Velocity measurements, or by angiographic vessel 
diameter evidence. While Kaku et al. define vasospasm as a Transcranial Doppler mean 
flow velocity greater than 100 cm/sec or an increase of more than 30 cm/sec (Kaku et al, 
1992) , Firlik et al. report vasospasm by measuring percentage stenosis through angiogram 
analysis (Firlik et al, 1997). Frontera et al. include a definition for vasospasm, which is 
defined by the development of new focal neurological symptoms or deficits after other 
causes have been excluded (Frontera et al, 2011). Below, Table 1 reports the variation in 
definitions of vasospasm used by different studies in this literature review. 
3. Pharmaceutical, non-endovascular treatments of vasospasm 
While studies investigating endovascular therapy for cerebral vasospasm are mostly 
retrospective with a small sample size, a group of prospective, randomized, controlled trials 
on the efficacy of non-endovascular, pharmaceutical treatment of vasospasm does exist. 
Recent trials have investigated the efficacy of statins, calcium channel blockers, a 
nonglucocorticoid aminosteroid, recombinant tissue plasminogen activator, and an 
endothelin receptor antagonist in vasospasm therapy. Although this review focuses on 
endovascular treatments for vasospasm, the future of vasospasm therapy also involves non-
endovascular treatments. 
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First Author Date/Journal Definition of Vasospasm 
Keuskamp 2008, J Neurosurg 
Angiographic CT 0, no vasospasm. Mild <20%, Mild Moderate 21-40%, 
moderate 41-60%, moderate-severe 61-80%. Severe >81%  constriction 
Firlik 1997, J Neurosurg 
Angiographic CT 0, no vasospasm. Mild, <50% stenosis. Moderate 50% 
stenosis. Severe >50% stenosis. 
Kaku 1992, J Neurosurg 
Symptomatic (new neurological deficit not attributable to other causes) 
and TCD velocity >100 cm/sec 





25% decrease in the vessel diameter was defined as mild, moderate 





on TCD measurements alone, VMCA >120 cm/s and HR 








TCD > 120 cm/s 
Retrospective CT angiography 0 , no vasospasm; 1, vessel narrowing 
less than 70%; 2, vessel narrowing greater than 70%; or 3, subtotal 
occlusion with high-grade hemodynamic compromise 
Symptomatic (50% decrease in somatosensory evoked potential 
amplitutde, increase in somatosensory evoked potential latency or 
increase of greater than 150 cm/second, or clinical vasospasm by new 
neurological deficit or loss of two points on GCS), decrease to less than 
15 mmHg in tissue oxygenation; also verified via digital subtraction 
angiography 
Beck 2006, J Neurosurg 
TCD velocity >120 cm/s in presence of Lindegaard index of>3 and 
severe vasospasm recorded was >200 cm/s 
Zweinenberg
-Lee 




Symptomatic (delayed neuronal deficits not explained by 




TCD velocities; between 150 and 200 cm/s mild vasospasm and >200 




Angiographic (mild vasospasm <50% reduction in vessel diameter, 
moderate = 50% reduction, severe >50% reduction 




Angiographic; <30% luminal narrowing mild, between 30 and 60% 
moderate, and over 60% severe 
Jun 2010, AJNR Angiographic; decrease in 50% or more in diameter of vessel segment 
Choi 
2011, J Korean 
Neurosurg 
Symptomatic (new focal neurological deficit not attributable to seizure, 




 Symptomatic and Angiographic (clinical, not defined greater than 50% 




Symptomatic defined by onset of delayed neurological deficit with 2 or 
more decrease on GCS 
 
Table 1.  
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a. Statin therapy 
The statins, or 3-hydroxy-3-methylglutaryl coenzyme A (HMGCoA) reductase inhibitors, 
have been theorized to have a protective role in the development of cerebral vasospasm. In 
addition to inhibiting the synthesis of cholesterol, statins are also thought to regulate 
endothelial and nitric oxide synthase function (Al-Tamimi et al, 2010), and therefore might 
affect the spasticity of the cerebral vasculature. Two statins, specifically simvastatin and 
pravastatin, have been investigated in randomized, placebo-controlled, trials. The results on 
simvastatin treatment of cerebral vasospasm have been mixed. While Vergouwen et al.  find 
that simvastatin treatment provided no improvement on TCD-defined vasospasm 
(Vergouwen et al, 2009), Chou et al. report that angiographic vasospasm was present in 
5/19 patients treated with simvastatin compared with 8/20 patients given a placebo (Chou 
et al, 2008). No differences, however, are statistically significant.  In their meta-analysis, 
Etminan et al. include only 190 patients and find this number to be too small to make 
conclusions about the efficacy of statin therapy (Etminan et al, 2011). 
b. Calcium antagonist therapy 
Nimodipine, a calcium antagonist and part of the current standard of care for treatment of 
cerebral vasospasm, inhibits calcium entry. However, other pathways exist within the cell 
that affect calcium utilization and also serve as possible targets for the treatment of 
vasospasm. In a prospective, randomized, placebo-controlled, double-blind trial, Shibuya et 
al. investigated the efficacy of AT877, an inhibitor of myosin light-chain kinase, of protein 
kinases A,G, and C, and of the actions of free intracellular calcium ions (Shibuya et al, 1992). 
With intravenous therapy of AT877, Shibuya et al. report a statistically significant reduction 
of angiographic vasospasm by 38% as well as a reduction in symptomatic vasospasm by 
30%. Clinically, Shibuya et al. find AT877’s effect on outcomes to be similar to nimodipine’s; 
the article reports a significant reduction in poor outcomes associated with vasospasm by 
54% and finds no significant adverse side effects (Shibuya et al, 1992). A possible downside 
of treatment with AT877 is its short half-life. Although Shibuya et al. report that AT877’s 
metabolite still shows spasmolytic qualities, the parent compound has an estimated half-life 
of under fifteen minutes.  
c. Treatment with tirilizad mesylate 
In response to the possible connection between free radical-induced lipid peroxidation and 
vasospasm, the 21 aminosteroid, tirilazad meslyate, was created to inhibit this pathway 
(Kassell et al, 1996). In a prospective, randomized, double-blind, controlled trial of 1023 
patients, Kassell et al. investigated the efficacy of tirilazad mesylate, using symptomatic 
vasospasm and Glasgow Outcome Scale scores at three months as outcome measures. 
Although Kassell et al. do not report a statistically significant reduction in symptomatic 
vasospasm with aSAH after treatment with tirilazad mesylate, they argue for the presence 
(p=.048) of a decrease in vasospasm at higher doses of tirilazad mesylate. The most 
promising statistics from this article, however, concern the three month outcomes for 
patients in the treatment group. Kassell et al. report in the highest dosage of tirilazad 
mesylate,  63% of patients had a good recovery, compared to 53% of the vehicle treated 
group (Kassell et al, 1996). This difference was statistically significant. Despite minor 
injection site phlebitis, tirilazad mesylate was not associated with life-threatening or adverse 
medical events.  
d. Endothelin receptor antagonist therapy 
Systemic vasoconstriction is controlled by many physiological hormones, including 
adrenergic agonists, angiotensin II, and antidiuretic hormone.  Endothelin, a powerful 
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vasoconstrictor possibly increased after aSAH (Macdonald et al, 2008) and its pathway to 
vasoconstriction have been investigated for possible targets in the treatment of vasospasm. 
Specifically, Macdonald et al. looked at the efficacy of the endothelin receptor antagonist, 
clazosentan, in the prospective, randomized, double-blind, placebo-controlled 
CONSCIOUS-1 trial. While Macdonald et al. report no significant difference between the 
treatment and control groups with respect to morbidity and mortality, they find a reduction 
of moderate or severe vasospasm from 66% in the placebo group to 23% in the highest 
dosage treatment group (Macdonald et al, 2008). Complications associated with clazosentan 
administration included anemia, hypotension and pulmonary issues including pneumonia, 
pleural effusions, pulmonary edema, and acute respiratory distress syndrome. The results of 
the CONSCIOUS-1 trial point to the disconnect between vasospasm and clinical outcome. 
While Macdonald et al. report a decrease in vasospasm from digital subtraction 
angiography after treatment, they find no effect on morbidity and mortality (Macdonald et 
al, 2008). Like other studies in this review of the literature, this trial calls for further 
exploration in the connection between vasospasm and clinical consequences.  
e. Fibrinolytic therapy 
The correlation between subarachnoid clot thickness and degree of vasospasm led to the 
possibility of fibrinolytic therapy in the treatment of cerebral vasospasm. In a prospective, 
randomized, blinded, placebo-controlled trial by Findlay, the efficacy of intracisternal, 
recombinant tissue plasminogen activator for prevention of vasospasm was investigated 
with angiographic vasospasm serving as the primary endpoint (Findlay, 1995)  Although 
Findlay reports angiographic vasospasm in 74.4% of placebo patients and 64.6% of 
treatment patients, the difference between the two groups was not statistically significant 
(P=.31) An interesting, significant finding from the same study comes from the treatment of 
patients with thick subarachnoid clots. In this group, Findlay finds a 56% relative risk 
reduction  of severe vasospasm in the treatment group, suggesting a very specific indication 
for treatment with recombinant tissue plasminogen activator. While Findlay also reports a 
pattern of lower mean velocities on transcranial Doppler, reduced delayed neurological 
worsening, a lower 14 day mortality rate, and improved 3 month outcome in the treatment 
group, none of these findings was statistically significant (Findlay, 1995). As with all 
fibrinolytic treatment, the possibility of treatment associated hemorrhage presents as a risk.  
While these studies, investigating the efficacy of pharmaceutical, non-endovascular 
treatments of vasospasm, are well-designed and have promising results, future larger scale, 
multi-center trials, with mortality serving as a primary outcome measure, would help 
determine which therapies should be added to the standard protocol for treatment of 
cerebral vasospasm.  
4. Current institutional protocols for treatment of aSAH and vasospasm 
While a standard of care has not been completely established for the treatment of cerebral 
vasospasm, common themes are ubiquitous throughout a review of the literature. After 
diagnosis of aSAH, the following treatment can be divided into two sections, common to 
most recent studies.  The first part of therapy involves stabilizing the patient’s aSAH while 
the second focuses on the prevention or management of cerebral vasospasm. Before cerebral 
vasospasm is even considered, the aSAH is ideally treated surgically by either endovascular 
coiling or clipping.  However, the timing of surgery, similar to the definition of cerebral 
vasospasm, has not been completely standardized. While Choi et al.’s protocol (Choi et al, 
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2011) calls for surgery within twenty four hours of the aSAH, Murai et al. include patients 
whose aneurysms had been clipped or coiled within forty eight hours of aSAH (Murai et al, 
2005). After the subarachnoid hemorrhage has been managed surgically, the goal of therapy 
begins to focus on the treatment of cerebral vasospasm.  
Typically after surgery today, patients are then treated with oral nimodipine and a 
combination of induced hypertension, hemodilution, and volume expansion (“Triple-H”) 
therapy to minimize the effects of cerebral vasospasm (Komotar et al, 2008). Nimodipine, a 
dihydropyridine calcium channel blocker, which blocks L-type, slow conducting, voltage-
dependent, calcium channels, has been shown to reduce cerebral infarction, when compared 
to untreated patients (Weant et al, 2010) , while triple-H therapy focuses on maintaining 
high cerebral perfusion pressures to increase cerebral blood flow during vasospasm 
(Komotar et al, 2008). 
These treatments, however, are not applied without controversy. With Triple-H therapy 
comes the risk of possible organ damage, pulmonary edema, and organ ischemia. On the 
other hand, the use of nimodipine in the treatment of cerebral vasospasm has raised 
questions about the connection between cerebral vasospasm and poor outcomes. 
Mechanistically, the administration of a calcium channel blocker “makes sense”; prevention 
of an increasing concentration of intracellular calcium should reduce smooth muscle 
contraction within the cerebral vasculature.   
While Pickard et al. do report a significant reduction in cerebral infarction events in those 
treated with nimodipine after aSAH (Pickard et al, 1989), they do not find a change in 
Transcranial Doppler Velocities between those treated and the controls. It has been 
suggested that antithrombotic actions of nimodipine might be responsible for its therapeutic 
effects (Weant et al, 2010). Nimodpine’s clinical benefits without changing Transcranial 
Doppler Velocities suggests that vasospasm may be correlated with adverse clinical 
outcomes but may not cause them. Similarly, Frontera et al. report that a Transcranial 
Doppler Velocity greater than 120 cm/sec, a measurement indicative of vasospasm, is not 
necessarily a predictor of clinical outcome (Frontera et al, 2009).  A recent meta-analysis by 
Etminan et al., investigating the efficacy of pharmaceutical treatment on delayed cerebral 
ischemia (DCI), also reported a decrease in radiographic vasospasm without clinical benefit 
(Etminan et al, 2011). The exact relationship between vasospasm and clinical outcome must 
still be fully elucidated.  
Although nimodipine and Triple-H therapy have been shown to improve clinical outcome, 
even administration of these therapies are not standardized. While Zweinenberg-Lee et al. 
report a protocol (Zwienenberg-Lee et al, 2008) of maintaining hematocrit levels between 30-
35%, Oskouian et al.’s protocol (Oskouian et al, 2002) calls for a target of 31-35%. Similarly, 
across these studies on the treatment of vasospasm, a common, unifying goal of 
hypertensive therapy is not present.  Rosenwasser et al. report elevating mean arterial 
pressure to 130-140 mm Hg (Rosenwasser et al, 1999), while Oskouian et al. present a 
protocol calling for a perfusion pressure of 70 mm Hg (Oskouian et al, 2002) and Coyne et 
al. report a maintenance level of 240 mm Hg for systolic blood pressure (Coyne et al, 1994). 
The methods to achieve high levels of cerebral blood flow and hypertension are also not 
standardized.  While Keuskamp et al. report using neosynephrine, ephedrine, and 
dopamine in their triple-H therapy (Keuskamp et al, 2008), Murai et al. use dobutamine 
alone (Murai et al, 2005).  Therefore, the current “gold standard,” a combination of Triple-H 
therapy and nimodipine, is not uniformly executed.  
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5. Experimental endovascular treatments for vasospasm 
Besides medical therapy with intravenous or oral nimodipine and Triple-H therapy, cerebral 
vasospasm after aSAH, has been experimentally treated with methods that are theoretically 
sound. While nitric oxide donors, phosphodiesterase inhibitors, endothelin antogonists, 
statins, and magnesium (Weant et al, 2010; Fathi et al, 2001; Shankar et al, 2011) have all 
been investigated for treating cerebral vasospasm through expected vasodilatory effects, the 
focus of current endovascular studies has predominantly remained on intra-arterial medical 
therapy with the calcium channel antagonist ,verapamil ,or the posphodiesterase inhibtor, 
papaverine, or transluminal balloon angioplasty of the affected vessels. 
a. Intra-arterial medical treatment and its efficacy 
The methods of administering intra-arterial medical therapy differ slightly from group to 
group and depend on the specific article from the review of the literature. A representative 
technique, however, is described by Feng et al . A 5F or 6F guiding catheter is used to infuse 
the specified drug in the internal carotid or vertebral arteries. With this technique, the 
physician hopes to deliver medical therapy to the spastic vessels (Feng et al, 2002). Some 
groups, such as Jun et al., report a slightly different protocol if severe vasospasm is present 
in the ACA or MCA.; they describe using a microcatheter  to reach the spastic portions of 
the ACA and MCA to deliver medical therapy (Jun et al, 2010). 
Although most studies evaluating the efficacy of intra-arterial medical therapy and 
angioplasty are retrospective with a relatively small sample size, they do show some 
promise in the treatment of cerebral vasospasm. While Kaku et al. report an improvement in 
neurological function in 80% of patients treated with intra-arterial papaverine (Kaku et al, 
1992), Keuskamp et al. describe a median reduction of 2 units on their vasospasm scale after 
treatment with intra-arterial verapamil (Keuskamp et al, 2008). However, the data on intra-
arterial medical treatment of cerebral vasospasm are not completely straightforward; 
Coenen et al. report that the benefits from intra-arterial papaverine administration are 
neither reliable nor sustained. Another problem that arises in comparing studies, evaluating 
the efficacy of intra-arterial medical treatment, is the dosage of drug administered (Coenen 
et al,  1998). While Kassell et. al use 100-300 mg of papaverine in their protocol (Kassell et al, 
1992) , Firlik et al. report using between 300 and 600 mg of the same drug (Firlik et al, 1997). 
It is difficult to generalize the efficacy of intra-arterial medical therapy given the variety of 
dosage protocols across studies in this literature review. 
However, intra-arterial treatment of cerebral vasospasm does not come without risk.  
Investigating the risks of intra-arterial verapamil infusion and papaverine therapy 
respectively, Feng et al. and Keuskamp et al. find no significant changes in intracranial 
pressure, heart rate, or hemodynamic parameters after intra-arterial treatment (Feng et al, 
2002; Keuskamp et al, 2008).  These are not the only parameters, however, by which safety of 
intra-arterial therapies should be assessed. Intra-arterial administration of papaverine and 
verapamil have both been associated with case reports of seizures (Zubkov et al, 1984) while 
papaverine alone has been linked to aphasia, mental status changes, and even respiratory 
arrest. On the cellular level, papaverine might also adversely affect neuronal mitochondrial 
respiration (Weant et al, 2010). Although Feng et al. and Keuskamp et al. report that intra-
arterial therapy is safe, further research should be conducted before verapamil or 
papaverine use is widely accepted as treatment for vasospasm.  
b. Angioplasty for cerebral vasospasm and its efficacy 
Beginning in 1984, the treatment of cerebral vasospasm after aSAH came to include the 
physical dilation of cerebral arteries using transluminal balloon angioplasty. The original 
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technique of angioplasty, described by Zubkov et al., involved puncturing the common 
carotid artery and placing a balloon catheter in the internal carotid artery. In an X-ray room, 
the balloon catheter was then repetitively inflated and deflated in the proximal part of the 
affected artery. This procedure then continued distally and after this technique, cerebral 
blood flow was monitored with a Xe-133 administration (Zubkov et al, 1984).  
Since Zubkov’s original paper, the actual technique of angioplasty has progressed at a 
relatively slow rate; today, angioplasty very much resembles the original procedure 
performed by Zubkov, including the repetitive inflation-deflation cycles.  Similar to the 
description of intra-arterial medical treatment for vasospasm, the current techniques of 
angioplasty differ slightly from group to group and depend on the specific article from the 
literature. A representative method of angioplasty for cerebral vasospasm is described by 
Jun et al (Jun et al, 2010).  In this study, Jun et al. report intravenous heparinization prior to 
angioplasty. Unlike Zubkov et al., they begin treating the distal portions of the spastic artery 
before the proximal portions.  Although angioplasty for cerebral vasospasm has shown 
promise with respect to clinical outcomes, the technique is not without limitations. Terada et 
al. and Jun et al. both exclude smaller, distal cerebral arteries as targets of treatment with 
angioplasty for fear of vessel rupture (Terada et al, 1997; Jun et al, 2010). While each group 
“sets their own limits” with respect to the smallest vessel they will treat with angioplasty, 
Jun et al. report treating vasospasm in the supraclinoid ICA, M1 MCA, A1 ACA, intracranial 
vertebral artery, basilar artery, and P1 PCA (so called “proximal vessels”), while they find 
treatment of M2 MCA, A2 ACA, P2 PCA (so called “distal vessels”) to be too risky (Jun et al, 
2010). With every procedure comes the possibility of complications. While the risks of 
mechanical dilation of spastic cerebral vessels by transluminal angioplasty are lessened by a 
skilled physician, they are still present. Vessel rupture, thrombosis, and occlusion are 
possible complications during the angioplasty procedure (Weant et al, 2010). 
Since Zubkov’s paper, studies have investigated the efficacy of his technique.  Overall, the 
results of cerebral angioplasty have been promising; in a 50 patient pilot study, Eskridge et 
al. report a 61% sustained neurological improvement after angioplasty (Eskridge et al, 1998). 
Although most studies in this literature review look positively upon angioplasty for cerebral 
vasospasm, not all trials have proven to be efficacious. While Fujii et al. and Eskridge et al., 
respectively, describe an 83% increase in diameters of affected cerebral arteries (Fujii et al, 
1995) and a 73% recovery in patients experiencing focal neurological deficits after treatment 
(Eskridge et al, 1990), Coenen et al. find angioplasty to be an unreliable method of treating 
cerebral vasospasm. Similar to other conclusions made in this literature review, the results 
of these retrospective angioplasty trials do not provide a straightforward judgment on its 
efficacy (Coenen et al, 1998).  
Once again, comparing these studies, which assess the efficacy of angioplasty for cerebral 
vasospasm, is difficult given the absence of standardization of the procedure. One 
difference, amongst groups, lies in the type and size of balloon used during angioplasty. For 
example, while Eskridge et al. use a 3 mm. x 12 mm. silicone balloon from Target 
Therapeutics (Eskridge et al, 1998) , Bejjani et al. report using a 3.5 mm. Cirrus balloon 
(Bejjani et al, 1998).  While these differences might not practically affect the procedure or its 
results, they should be considered when evaluating the efficacy of this technique. 
c. Comparison of angioplasty with intra-arterial medical therapy 
Although retrospectively, the efficacy of intra-arterial medical therapy and angioplasty for 
vasospasm have been compared. Similar to the studies on the efficacy of both of these 
modes of treatment, the groups comparing these two therapies have produced mixed 
www.intechopen.com
Evidence-Based Invasive Treatments for Cerebral  
Vasospasm Following Aneurysmal Subarachnoid Hemorrhage 
 
113 
results.  Elliott et al. report a favorable clinical outcome in 67% of patients after angioplasty 
compared with a 62% favorable outcome after treatment with papaverine (Elliott et al, 1998), 
while Katoh et al. report a 58% clinical improvement after angioplasty compared with a 25% 
improvement after papaverine (Katoh et al, 1999). Elliiott et al. also report an increase in 
Transcranial Doppler velocities on Day 2 after treatment with papaverine, suggesting an 
absence of sustainable effect from the papaverine (Elliott et al, 1998). Although these studies 
suggest that angioplasty is a more effective endovascular treatment for cerebral vasospasm, 
the data are not all one-sided. Coenen et al. report that both angioplasty and papaverine are 
equivalently ineffective in producing reliable and sustained results (Coenen et al, 1998). 
Theoretically, an interesting procedure would be combining both angioplasty and intra-
arterial medical therapy in the same treatment. 
d. Combination therapy with angioplasty and intra-arterial medical treatment 
Since it is believed that angioplasty in smaller, more distal vessels, is too risky, it is logical 
that a combination of intra-arterial medical treatment with angioplasty might be effective in 
treating both proximal and distal cerebral vasospasm. In a retrospective study by Frontera et 
al. the group compares combined therapy with chemical vasodilation alone. Frontera et al. 
find that while 39% of patients undergoing combination therapy developed recurrent 
angiographic and symptomatic vasospasm, 82% of patients receiving chemical vasodilation, 
alone, developed vasospasm (Frontera et al, 2011).  Future, large-scaled and multicenter 
trials on the efficacy of combination therapy should help elucidate the most effective 
combinations of medical endovascular treatment with angioplasty. 
Amongst these experimental, endovascular treatments, angioplasty seems beneficial for the 
larger, more proximal, and more accessible cerebral vessels while treatment with intra-
arterial papaverine and verapamil is more appropriate for smaller, more distal, and less 
accessible arteries where a large risk of rupture is present.  
6. Limitations to efficacy comparisons across studies 
However, problems with these studies, investigating the efficacy of experimental treatments 
for cerebral vasospasm, do exist. The small sample sizes and retrospective nature of a vast 
majority of these studies make it difficult to establish definitive conclusions with respect to 
efficacy of different endovascular treatments. Also, the criteria to begin endovascular 
treatment differ from group to group. For example, while Bejjani et al report treating 
vasospasm with angioplasty only after Triple-H therapy has failed (Bejjani et al, 1998) , 
Santillan et al. use a decrease in vessel diameter via angiography as one if their indications 
for treatment (Santillan et al, 2011). Therefore, constructing a meta-analysis, combining the 
results of these studies, is difficult as different groups make their own decisions about when 
to treat patients endovascularly. Table 2, below, lists the criteria to treat cerebral vasospasm, 
from several groups, reviewed in the literature.  
7. Recommendations for invasive treatments 
Although most experimental studies investigating the efficacy of invasive treatments for 
cerebral vasospasm after aSAH are retrospective in nature, effective patterns can be 
extracted from these studies. From the studies in this literature review, it appears that 
Triple-H therapy combined with administration of nimodipine is the first line of treatment 
or prevention of cerebral vasospasm. Once the vasospasm is deemed refractory to this  
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Author/Date Indication for Endovascular Treatment 
Feng, 2002 Verapamil was given  “to prevent catheter-induced vasospasm,”  for treatment 
of mild vasospasm that did not warrant angioplasty, and for the treatment of 
moderate to severe vasospasm that could not be safely treated with angioplasty 
Firlik, 1997 CBF new region < 20 ml/100 g/minute were treated with angioplasty 
Bejjani, 1998 Do angioplasty after failed HHH therapy; digital subtraction angiography 
performed first. 
Kaku 1992 Angioplasty (to deliver papaverine) if onset of new neurological deficit 
not attributable to other causes,  no evidence of infarction on CT, unsuccessful 
treatment of neurological deficit by conventional medical and pharmacological 
therapies, mean flow velocity 100 cm/sec or increase in mean flow 
velocity greater than 30 cm/sec w/in 24 hours in affected vessel by TCD, and 
vasospasm seen angiographically in location consistent with neurological 
deficit. 
Terada, 1997 Endovascular therapy if  new neurological signs appear after SAH, not deriving 
from hematoma, brain edema, or hydrocephalus, neurological signs are related 
to vascular territory of vasospasm, vessel diameter is less than 50% of initial 
diameter angiographically, no low density area is related to vasospasm on CT, 
clinical signs progress despite medical treatment, and ruptured aneurysm has 
been treated 
Andaluz, 2002 Refractory vasospasm (not clearly defined) to HHH therapy; included if  all 
aneurysm clipped or coiled before Day 3 after SAH, clinical vasospasm defined 
by the presence of a new neurologic deficit not explained by hydrocephalus, 
infection, electrolyte imbalance, or other medical complication, clinical 
vasospasm in patients treated with nimodipine and with symptoms not 
reversed by maximal HHH treatment, and endovascular therapy instituted 
w/in 12 hours of onset of symptoms 
Eskridge, 1998 hypertensive therapy started if suspicion of vasospasm; angioplasty if  new 
onset of a neurological deficit not attributable to other causes, no evidence of 
established cerebral infarction on CT scans, deficit persisting despite 
hypertensive, hypervolemic therapy, and angiographic evidence of vasospasm 
in a distribution that could explain the deficit 
Rosenwasser, 1999 If new deficit, CT scan to eliminate hydrocephalus or bleeding. HHH therapy 
maximized to elevate MAP to 130-140 mm Hg. If not reversible then go to get 
angioplasty 
Jestaedt, 2008 Clinical symptoms or high grade vessel narrowing (>70%) 
Beck, 2006 HHH protocol; symptoms still then get MR;  if PW DW mismatch then continue 
HHH; then DS angiography then TBA 
Zwienenberg-Lee, 
2008 
Randomized to either angioplasty or no angioplasty 
Frontera 2011 All patients digital subtraction angiography; vessels which responded to IACV 
and could not be treated with angioplasty only IACV; accessible vessels with 
residual vasospasm  after IACV then TBA 
Eskridge, 1990 Inclusion criteria included  new onset of a neurologic deficit after subarachnoid 
hemorrhage that was not attributable to other causes, such as hydrocephalus, 
hematoma, mass effect,  no evidence of infarction on CT scan, neurologic deficit 
not reversed by hypervolemic and hypertensive therapy, and angiographically 
apparent vasospasm in location responsible for deficit 
Muizelaar, 2001 All patients had SAH and Fisher Grade III on CT scan w/in first two days of 
SAH; had to have surgical or neurointerventional treatment of ruptured 
aneurysm; then TBP could be performed 
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Fujii, 1995 developed symptomatic vasospasm in spite of intensive medical supportive 
therapy including hypertension, volume expansion, and administration of brain 
protective agents, the cases whose showed either consciousness deterioration 
worse than 30 in Japan Coma Scale and/or distinct neurological deficit, and 
cases whose angiogram performed as early as possible after emergence of 
symptoms showed the responsible narrowing in intracranial arteries. 
Jun, 2010 Severe proximal CV (luminal narrowing >60%) treated with PTA and distal CV 
(luminal narrowing >30%) with verapamil 
Choi, 2011 CT scan in patients with clinical deterioration; vasospasm defined as increase in 
TCD flow to 150 cm/second. If greater than 150 cm/second, MRI, DWI and 
MRA; if infraction or narrowing by MRA, angioplasty was recommended 
Santillan, 2011 Indication for TBA  neurological deficits were referable to vascular territory of 
the VSP angiographically, vessel diameter less than 50% of initial diameter 
angiographically, no evidence of hypodensity on non-contrast head CT scan 
suggestive of ischemic infarct due to VSP prior to angiogram, and baseline 
diameter of vessel on initial cerebral angiogram or CT was not less than 
approximately 2 mm in size. 
Murai, 2005 DINDs assumed vasospasm if between 3-14 days after SAH; some had 
angiograms to determine vasospasm (50% or more narrowing when compared 
to admission CT); heparinization w/angioplasty if deficit could be related to 
distribution of vasospasm 
Coyne, 1994 Symptomatic vasospasm defined as onset of delayed neurological deficit (2 or 
more decrease on Glasgow Coma Scale); treated initially with hypervolemia, 
hypertensive therapy; maintain a capillary wedge pressure of 14 to 18 mm Hg. 
Maintain a systolic BP of 240 mm HG in clipping or 160 mm HG in unclipped; 
angioplasty if neurological deficit/CT showed no improvement 
Table 2. 
treatment, invasive treatments should be employed next. A combination of verapamil or 
papaverine to treat distal vasospasm with angioplasty to treat proximal vasospasm in larger, 
more available vessels falls in line with conclusions of many of the studies reviewed. Timing 
of invasive treatments may also prove to be critical. Rosenwasser’s retrospective study finds 
improved clinical and angiographic outcomes in patients treated with angioplasty within a 
two hour window (Rosenwasser et al, 1999). Therefore, combined intra-arterial treatment 
with either papaverine or verapamil and angioplasty within a timely manner appears to be 
the most effective treatment.  
8. Unclear role of vasospasm in clinical outcomes 
A review of the literature on invasive treatments for cerebral vasospasm has highlighted a 
possible disconnect between the presence of cerebral vasospasm and clinical outcome. 
Frontera’s group and Macdonald’s group respectively find that Transcranial Doppler 
Velocities (Frontera et al, 2009) and angiography (Macdonald et al, 2008), consistent with 
cerebral vasospasm, are not necessarily predictors of a specific clinical outcome. These 
findings have led to the hypothesis that other mechanisms, after aSAH, may be responsible 
for poor clinical outcomes. Specifically, early brain injury, before the onset of vasospasm, 
has been explored. Classically, cerebral vasospasm is thought to occur between four and 
nine days after the ictus. Early brain injury, defined as injury within 72 hours of the aSAH, 
may provide insight into poor clinical outcomes after aSAH (Pluta et al, 2009). Within these 
72 hours, early brain injury has been associated with an elevation of intracranial pressure, a 
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reduction in cerebral blood flow, blood-brain barrier disruption and neuronal cell death 
(Pluta et al, 2009). These changes, and not cerebral vasospasm, may be responsible for the 
subsequent clinical outcome.  
Another recently proposed mechanism for the development of poor clinical outcomes has 
also been suggested. A mixture, similar to that of cerebrospinal fluid after SAH, has been 
shown to cause spreading cortical depolarization after application to the subarachnoid space 
(Pluta et al, 2009). This, in turn, has led to eventual ischemia and cortical necrosis. Similarly, 
13 out of 18 patients, receiving surgical treatment after aSAH, have been shown to have 
similar waves of depolarization, consistent with the start of clinical deterioration (Pluta et al, 
2009). Therefore, in addition to vasospasm, early brain injury and spreading cortical 
depolarization should be investigated for their importance in clinical outcomes.  
9. Future directions in the treatment of cerebral vasospasm 
Theoretically, endovascular therapy for cerebral vasospasm may include treatments other 
than intra-arterial pharmaceutical administration and cerebral artery angioplasty. Komotar 
et al. mention the possibility of using intra-aortic balloon counterpulsation to treat 
vasospasm. In this technique, an aortic balloon is placed distally to the origin of the left 
subclavian artery endovascularly. During diastole, the balloon inflates, redirecting blood to 
the coronary, carotid, and vertebral arteries in this part of the cardiac cycle (Komotar et al, 
2008). The balloon then deflates during systole. The authors of this study report an average 
increase in cerebral blood flow by 69.3% (Nussbaum et al, 1998). Since the goal of Triple-H 
therapy is to improve cerebral blood flow, the intra-aortic balloon might be used in 
combination therapy with medical treatment for the reduction of cerebral vasospasm and 
ischemia after aSAH.  As this device is implanted in the femoral artery, risks such as 
hemorrhage and dissection of the femoral artery are present (Komotar et al, 2008). A case 
report, by Appelboom et al., describes a similar procedure with a Neuroflo, intra-aortic, dual 
balloon catheter. In this report, two balloons, one above and one below the renal arteries, are 
inflated to redirect blood flow to the cerebral arteries during refractory vasospasm. An 
advantage of this technique is the avoidance of complications associated with direct 
manipulation of cerebral vasculature (Appelboom et al, 2010).  
The future of cerebral vasospasm therapy depends on further elucidation of the 
pathophysiology of this condition. Komotar et al. report initial success with another free 
radical trapping agent. Just like tirilizad mesylate, disodium 2,4-disulfophenyl-N-tert-
butylnitrone inhibits lipid peroxidation and has been associated with improvement in 
neurological function in primates (Komotar et al, 2008). Other evidence has suggested that 
the pathogenesis of vasospasm may depend on the immune system. Preventing the 
interaction between leukocytes and endothelial cells with blocking antibodies has also 
inhibited vasospasm after aSAH (Baybek et al, 1998). Similarly, patients undergoing therapy 
with steroids have a lower risk of developing delayed ischemic deficits after aSAH (Chyatte 
et al, 1987). The interplay between the immune system and development of cerebral 
vasospasm needs to be further investigated before immune modulating therapy can be 
directed towards the treatment of vasospasm.  
10. Conclusion 
A review of the literature on endovascular treatment for cerebral vasospasm has suggested 
the need for commonly used protocols and definitions to determine the efficacy of these 
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therapies. Although most studies in this review provided protocols that used Triple-H  
therapy and nimodipine as a first line treatment for cerebral vasospasm, the variation in 
institutional protocols in these studies made comparisons difficult. Similarly, the absence of 
a unifying or “gold standard” definition of vasospasm suggests that different indications in 
each study might call for the same treatment. Given that studies in this analysis use either 
CT angiography, symptoms, or Transcranial Doppler Velocities to assess for vasospasm, it is 
difficult to know if each study would treat the same patient for the same degree of 
vasospasm.  It is therefore difficult to compare the results of different studies, investigating 
the same treatment. Similarly, the actual endovascular therapy, either intra-arterial medical 
treatment or transluminal angioplasty, was not the same in each study. Both the dosage of 
intra-arterial drug administered and the type and size of angioplasty balloon differed 
amongst the studies in this review of the literature.  
The retrospective nature and small sample size of an overwhelming majority of the studies 
in this review call for a newly designed, novel study in the endovascular treatment of 
vasospasm. Zweinenberg-Lee et al. provide data from a Phase II, Multicenter, Randomized, 
Clinical Trial assessing the effects of prophylactic angioplasty on infarction rates after 
cerebral vasospasm. The results of this trial, that prophylactic angioplasty provided an 
absolute risk reduction of 5.9% for developing an infarction after cerebral vasospasm 
(Zweienenberg-Lee et al, 2008), may serve as a model for future trials assessing the efficacy 
of endovascular treatments of vasospasm although not all the data were statistically 
significant. Future research on endovascular treatment of vasospasm should also follow the 
study design of trials investigating non-endovascular, pharmaceutical therapy for 
vasospasm. These studies, included in Etminan’s meta-analysis, are prospective, 
randomized, adequately blinded, and placebo or vehicle controlled (Etminan et al, 2011).  
This literature review has highlighted the need for a highly controlled, randomized, 
multicenter, clinical trial, assessing the efficacy of endovascular treatment. A randomized, 
controlled, clinical trial placing patients into either an intra-arterial papaverine group, an 
intra-arterial verapamil group, an intra-arterial papaverine and angioplasty group, an intra-
arterial verapamil and angioplasty group, and an angioplasty group alone would provide 
the groundwork for a standardized protocol for effectively treating cerebral vasospasm 
endovascularly. Similarly, future studies should investigate vasospasm’s role in affecting 
clinical outcomes and possible novel treatments. The future of vasospasm treatment, 
however, depends on further elucidation of the pathophysiology of vasospasm after aSAH. 
The role of the immune system and lipid peroxidation after aSAH should be investigated in 
the pathogenesis of this condition.  
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